Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis

Lancet Respir Med. 2024 Feb;12(2):e5-e6. doi: 10.1016/S2213-2600(23)00426-5. Epub 2023 Nov 30.

Authors

Sarah M Labuda¹, Barbara Seaworth², Shom Dasgupta³, Neela D Goswami⁴; BPaL Accelerated Monitoring Project Team

Affiliations

¹ US Centers for Disease Control and Prevention, Division of Tuberculosis Elimination, Atlanta, GA 30329, USA.
² Heartland National Tuberculosis Center, San Antonio, TX, USA.
³ Los Angeles County Department of Public Health, Los Angeles, CA, USA.
⁴ US Centers for Disease Control and Prevention, Division of Tuberculosis Elimination, Atlanta, GA 30329, USA. Electronic address: nef7@cdc.gov.

PMID: 38043563
DOI: 10.1016/S2213-2600(23)00426-5

No abstract available

Publication types

Letter

MeSH terms

Antitubercular Agents / therapeutic use
Diarylquinolines*
Humans
Linezolid / therapeutic use
Moxifloxacin / therapeutic use
Mycobacterium tuberculosis*
Nitroimidazoles*
Tuberculosis* / drug therapy
Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

bedaquiline
Moxifloxacin
Linezolid
pretomanid
Antitubercular Agents
Nitroimidazoles
Diarylquinolines